{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hantel A"],"funding":["NCI NIH HHS"],"pagination":["1046-1052"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10985457"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["109(4)"],"pubmed_abstract":["Clinical trial eligibility criteria can unfairly exclude patients or unnecessarily expose them to known risks if criteria are not concordant with drug safety. There are few data evaluating the extent to which acute leukemia eligibility criteria are justified. We analyzed criteria and drug safety data for front-line phase II and/or III acute leukemia trials with start dates 1/1/2010-12/31/2019 registered on clinicaltrials.gov. Multivariable analyses assessed concordance between criteria use and safety data (presence of criteria with a safety signal, or absence of criteria without a signal), and differences between criteria and safety-based limits. Of 250 eligible trials, concordant use of ejection fraction criteria was seen in 34.8%, corrected QT level (QTc) in 22.4%, bilirubin in 68.4%, as"],"journal":["Haematologica"],"pubmed_title":["Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia."],"pmcid":["PMC10985457"],"funding_grant_id":["K08 CA273043","U54 CA156732"],"pubmed_authors":["Warner E","Khan I","Abel GA","Walsh TP","Luskin MR","Patel AA","DeAngelo DJ","Lathan CS","Hantel A"],"additional_accession":[]},"is_claimable":false,"name":"Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.","description":"Clinical trial eligibility criteria can unfairly exclude patients or unnecessarily expose them to known risks if criteria are not concordant with drug safety. There are few data evaluating the extent to which acute leukemia eligibility criteria are justified. We analyzed criteria and drug safety data for front-line phase II and/or III acute leukemia trials with start dates 1/1/2010-12/31/2019 registered on clinicaltrials.gov. Multivariable analyses assessed concordance between criteria use and safety data (presence of criteria with a safety signal, or absence of criteria without a signal), and differences between criteria and safety-based limits. Of 250 eligible trials, concordant use of ejection fraction criteria was seen in 34.8%, corrected QT level (QTc) in 22.4%, bilirubin in 68.4%, as","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-07-16T14:53:23.988Z","creation":"2026-07-09T11:01:06.302Z"},"accession":"S-EPMC10985457","cross_references":{"pubmed":["37560812"],"doi":["10.3324/haematol.2023.283723"]}}